TRED-HF Trial Summary: Halliday et al. randomized 51 patients with dilated cardiomyopathy (LVEF<40%) who recovered with the improvement of symptoms to either continual treatment with HF medications or withdrawal of HF therapy. The objective was to assess the safety of withdrawing treatment in patients with dilated cardiomyopathy whose symptoms and cardiac function have recovered. The results showed significant replase..
Author: admin - page 2
DECLARE TIMI 58 Trial Summary: Wiviott et al. randomized 17,160 patients with DMII (HbA1c 6.5-12%) who had multiple risk factors for or had established atherosclerotic CV disease to either dapagliflozin or a placebo. Their objective was to assess the cardiovascular safety profile of dapagliflozin, a selective inhibitor of SGLT2 in patients with type 2 diabetes…
OPTIC Trial Summary: Stets et al. randomized 774 patients with community-acquired bacterial pneumonia (PSI risk class II, III, or IV) diagnosed clinically and with imaging to either omadacycline IV or moxifloxacin IV. The objective was to assess the role of omadacycline, a new tetracycline drug in the treatment of community-acquired bacterial pneumonia. The results showed similar early clinical..
MOMENTUM 3 Trial Summary: Mehra et al. randomized 366 patients with advanced HF (NYHA class III-IV, LVEF ≤ 25%), inotrope dependant, cardiac index < 2.2 without inotropes to either HeartMate III (centrifugal-flow LVAD) or HeartMate II (axial-flow LVAD). Their objective was to assess if is a magnetically levitated centrifugal-flow LVAD is superior to an axial-flow..
TRICC trial Summary: Hebert PC et al. randomized 838 critically ill patients with anemia Hb < 9.0 g/dL within 72 hours after the ICU admission to either restrictive transfusion strategy (Hb 7-9) or liberal strategy (Hb 10-12). The objective was to compare the effect of restrictive transfusion goal with a liberal transfusion goal on mortality..
TNT Trial Summary: LaRosa et al. randomized 10,001 patients with CAD defined by prior MI, prior or current anginal symptoms with evidence of CAD, prior revascularization to either high dose 80 mg atorvastatin or low dose 10 mg atorvastatin. Their objective was to assess if atorvastatin 80 mg PO daily have a greater reduction in..